Norepinephrine Injection Recalled for Lack of Sterility Assurance
Nephron Sterile Compounding Center is recalling 443,483 bottles of Norepinephrine Bitartrate injection nationwide due to lack of sterility assurance in the product.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Classified as FDA Class II. No illnesses or injuries reported, and the hazard is theoretical (lack of assurance) rather than confirmed contamination. However, lack of sterility in an injectable medication poses serious infection risk, justifying High severity.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP (8 mg/250 mL concentration, 250 mL single-dose containers).
The FDA classified this as a Class II recall due to lack of assurance of sterility in the product. Norepinephrine is a critical injectable medication used to treat low blood pressure in emergency and intensive care settings.
Approximately 443,483 bottles distributed nationwide are affected. The recalled lot numbers span from NB2015A (expiring 02/27/2023) through NB2061A (expiring 09/14/2023), representing 18 specific product lots.
The recalling firm is Nephron Sterile Compounding Center LLC, a 503B outsourcing facility located at 4500 12th Street Extension, West Columbia, SC 29172 (NDC 69374-316-25).
The recalled product
- Product
- Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP, 8 mg/250 mL (32 mcg/mL*), 250 mL Single-Dose Container, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-316-25.
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable Medication
- Affected units
- 443,483
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lots: NB2015A
- Exp. 02/27/2023
- NB2016A
- Exp. 02/19/2023
- NB2021A
- Exp. 03/05/2023
- NB2023A
- Exp. 03/12/2023
- NB2026A
- Exp. 03/29/2023
- NB2029A
- Exp. 04/21/2023
- NB2031A
- NB2033A
- Exp. 05/10/2023
- NB2034A
- Exp. 05/19/2023
- NB2037A
- Exp. 05/25/2023
- NB2039A
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Nephron Sterile Compounding Center LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same manufacturer · Nephron Sterile Compounding Center LLC
See all →- HighSodium Chloride Injection Recalled for Potential Sterility Compromise
FDA (Drugs) · 2025-03-19
- HighPhenylephrine HCl Injection Recalled for Sterility Assurance Deficiency
FDA (Drugs) · 2023-03-08
- HighNephron Phenylephrine HCl Injection Recalled for Sterility Assurance
FDA (Drugs) · 2023-03-08
- HighDiltiazem HCl Injectable Drug Recalled for Sterility Assurance Failure
FDA (Drugs) · 2023-03-08
- HighFDA Recalls Norepinephrine Injection Due to Sterility Concerns
FDA (Drugs) · 2023-03-08
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15